Philips shares gained modestly (+2.7%) following a quarter that largely met expectations, supported by steady order intake and margin expansion, though market reaction suggests investors were cautious on incremental upside.

• Order intake rose 6%, driven by strength in North America and disciplined growth across Diagnostic & Therapeutic (D&T) and Connected Care segments.
• Comparable sales increased 4% with broad-based growth in Personal Health and sustained momentum in key imaging modalities such as MRI and CT.
• Adjusted EBITDA margin expanded by 40 basis points to 9%, despite inflationary pressures including higher tariffs.
• Innovation momentum continued with 20 FDA clearances/pre-market approvals, notably delivering AI-enabled solutions in cardiac MRI, spectral CT, and image-guided therapy.
• Management reiterated full-year guidance reflecting confidence in execution amidst ongoing macro uncertainty, but the market’s tempered response implies vigilance on competitive and geopolitical risks.